A Rollover Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy

Status:	Active, not recruiting
Conditions:	Cardiology, Cardiology
Therapuetic Areas:	Cardiology / Vascular Diseases
Healthy:	No
Age Range:	18 - Any
Updated:	3/2/2019
Start Date:	February 2015
End Date:	February 2022

This is a rollover study designed to investigate the safety and effectiveness of
investigational study drug ARRY-371797 in patients who previously received ARRY-371797 in a
study for patients with LMNA-related dilated cardiomyopathy sponsored by Array BioPharma and
may, in the Investigator's opinion, derive benefit from continued treatment.

Key Inclusion Criteria:

- Received ARRY-371797 as treatment for a genetic dilated cardiomyopathy secondary to
LMNA mutations in a clinical study sponsored by Array BioPharma.

- May, in the opinion of the Investigator, benefit from continued ARRY-371797 treatment.

- Additional criteria exist.

Key Exclusion Criteria:

- Discontinued treatment in the parent study for any reason other than study completion
or Sponsor termination of the study.

- Additional criteria exist.

We found this trial at

sites

Brigham and Women's Hosp

75 Francis street
Boston, Massachusetts 02115

(617) 732-5500